Evidence Table C3: DISCRETE outcomes for class ANTI-BACTERIAL (TOPICAL).

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
	C.01.01			**Clindamycin + vehicle**	**Vehicle (oral) + vehicle (topical)**	
33 Parallel Mild N=87		**Diarrhea**	Mid (8)	Present 1	Present 1	
		Overall change/patient	Mid (8)	Marked improvement 19 Improved 3 No change 7 Worse 0	Marked improvement 0 Improved 1 No change 20 Worse 8	
		Overall change/physcian	Mid (8)	Excellent 17 Good 6 Fair 1 Poor 5	Excellent 0 Good 0 Fair 4 Poor 25	
	C.01.01			**Clindamycin hydrochloride**	**Vehicle**	
20 Parallel Mod N=358		**Diarrhea**	Mid (8)	Diarrhea due to medication 0 Diarrhea 6 No diarrhea 117	Diarrhea due to medication 0 Diarrhea 2 No diarrhea 111	
		Overall change/patient	Mid (8)	Worse 2 No change 26 Improved 68 Markedly improved 27	Worse 11 No change 38 Improved 52 Markedly improved 11	**0.003**
327 Parallel Mild/mod N=18		**Diarrhea**		Diarrhea 0	Diarrhea 0	
		Erythema		Erythema 3	Erythema 1	
		Itching		Burning /itching 3	Burning/itching 2	
		Peeling		Peeling 3	Peeling 2	
		Severity/patient	Mid (8)	Marked improvement 3 Some improvement 3 Slight improvement No change 3	Marked improvement 1 Some improvement Slight improvement 4 No change	
	C.01.01			**Clindamycin phosphate**	**Vehicle**	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
20 Parallel Mod N=358		**Diarrhea**	Mid (8)	Diarrhea due to medication 1 Diarrhea 5 No diarrhea 109	Diarrhea due to medication 0 Diarrhea 2 No diarrhea 111	
		Overall change/patient	Mid (8)	Worse 3 No change 13 Improved 76 Markedly improved 22	Worse 11 No change 38 Improved 52 Markedly improved 11	**0.003**
199 ↑ Parallel Mild/mod N=45		**Overall change/physician**	Mid (12)	Much improved 8 Improved 11 No change 1 Worse 1	Much improved 3 Improved 9 No change 2 Worse 0	
		Severe side effects	Mid (12)	Burning 0 Itching 1	Burning 1 Itching 1	
	C.01.02			**Clindamycin**	**Nicotinamide**	
305 ↓ Parallel Mod N=76		**Overall change/physician**	Short (4)	Much or moderately better 8	Much or moderately better 8	**NS**
		Local side effects	Mid (8)	Local site reactions 9	Local site reactions 10	
		Overall change/physician	Mid (8)	Much or moderately better 19	Much or moderately better 18	**NS**
	C.01.03			**Clindamycin (gel)**	**Clindamycin (solution)**	
267 ↓ Parallel Mild N=60		**Side effects**		Mild diarrhea 1 Upset stomach 0 Flare-up of acne 2 Skin dryness 3	Mild diarrhea 1 Upset stomach 1 Flare-up of acne 0 Skin dryness 9	
		Overall change/investigator	Mid (12)	Improved or markedly improved 25 Other 5	Improved or markedly improved 27 Other 3	
		Overall change/patient	Mid (12)	Improved 23 Other 7	Improved 28 Other 2	
	C.01.03			**Clindamycin (lotion)**	**Clindamycin (solution)**	
131 ↑ Parallel Mod/sev N=70		**Burning**	Short (6)	Present 6 Absent 26	Present 3 Absent 31	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
131 ↑ Parallel Mod/sev N=70		**Dryness**	Short (6)	Present 13 Absent 19	Present 17 Absent 17	
		Erythema	Short (6)	Present 11 Absent 21	Present 17 Absent 17	
		Itching	Short (6)	Present 7 Absent 25	Present 3 Absent 31	
		Peeling	Short (6)	Present 9 Absent 23	Present 5 Absent 29	
		Burning	Mid (12)	Present 2 Absent 30	Present 3 Absent 31	
		Diarrhea	Mid (12)	Present 1 Absent 31	Present 2 Absent 32	
		Dryness	Mid (12)	Present 13 Absent 19	Present 19 Absent 15	
		Erythema	Mid (12)	Present 13 Absent 19	Present 15 Absent 19	
		Itching	Mid (12)	Present 9 Absent 23	Present 4 Absent 30	
		Overall change/patient	Mid (12)	Marked improvement 4 Improved 18 No change 9 Worse 1	Marked improvement 5 Improved 18 No change 7 Worse 4	
		Overall change/physician	Mid (12)	Marked improvement 5 Improved 20 No change 6 Worse 1	Marked improvement 5 Improvement 19 No change 9 Worse 1	
		Peeling	Mid (12)	Present 6 Absent 26	Present 5 Absent 29	
	C.01.03			**Clindamycin hydrochloride**	**Clindamycin phosphate**	
20 Parallel Mod N=358		**Diarrhea**	Mid (8)	Diarrhea due to medication 0 Diarrhea 6 No diarrhea 117	Diarrhea due to medication 1 Diarrhea 5 No diarrhea 109	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
20 Parallel Mod N=358		**Overall change/patient**	Mid (8)	Worse 2 No change 26 Improved 68 Markedly improved 27	Worse 3 No change 13 Improved 76 Markedly improved 22	**0.003**
	C.01.04			**Clindamycin**	**Erythromycin**	
303 Parallel Mod N=178		**Inter-treatment preference/patient**	Mid (12)	Excellent 63 Other 25	Excellent 75 Other 5	**NS**
		Side effects	Mid (12)	Dropped out 0 Reduced dose 5 Other 12 None 69	Dropped out 1 Reduced dose 10 Other 12 None 58	
326 Parallel Mod/sev N=72		**Overall change/patient**	Mid (12)	Excellent + good 24 Other 12	Excellent + good 25 Other 11	**NS**
		Overall change/patient	Mid (12)	Excellent + good 24 Other 12	Excellent + good 25 Other 11	**NS**
	C.01.04			**Clindamycin phosphate**	**Erythromycin**	
158 ↑ Parallel Mod N=120		**Adverse reactions**	Mid (8)	Erythema/blistering 1 Diarrhea/vomiting 1 Acne exacerbation 1	Erythema/blistering 0 Diarrhea/vomiting 0 Acne exacerbation 0	
	C.01.05			**Clindamycin**	**Tetracycline**	
291 ↑ Parallel Mild N=92		**Severity assessment**	Mid (8)	Poor 1 Fair 13 Good 25 Excellent 5	Poor 11 Fair 10 Good 18 Excellent 4	**0.02**
		Side effects Between P-value: burning .05	Mid (8)	Itch 0 Irritation 0 Diarrhea 1 Vaginitis 1	Itch 1 Irritation 1 Diarrhea 1 Vaginitis 0	**NS**
				Hematuria 1	Hematuria 0	
	C.01.05			**Clindamycin**	**Tetracycline hydrochloride**	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
261 ↓ Parallel Mild/mod N=52		**Erythema**	Mid (8)	None 15 Mild 6 Moderate 1	None 19 Mild 8 Moderate 0	**NS**
		Itching/burn	Mid (8)	None 22 Mild 1 Moderate 0	None 23 Mild 4 Moderate 0	**NS**
		Overall improvement (discretized %)	Mid (8)	Good (67-100%) 10 Fair (34-66%) 10 Poor (<33%) 2	Good (67-100%) 7 Fair (34-66%) 7 Poor(<33%) 13	**0.01**
		Peeling	Mid (8)	None 22 Mild 1	None 25 Mild 2	**NS**
		Side effects	Mid (8)	Diarrhea 2 Film of yellow discoloration 0	Diarrhea 0 Film of yellow discoloration 26	
	C.03.01			**Erythromycin**	**Vehicle**	
184 ↑ Parallel Mod N=175		**Burning-irritation**	Mid (12)	Mild 3 Moderate 0 Severe 0	Mild 5 Moderate 6 Severe 1	
		Dryness	Mid (12)	Mild 3 Moderate 1 Severe 0	Mild 3 Moderate 1 Severe 1	
		Exudate	Mid (12)	Moderate 1	Moderate 0	
		Eye irritation	Mid (12)	Present 2	Present 0	
		Herpes simplex	Mid (12)	Mild 1	Mild 0	
		Oiliness	Mid (12)	Mild 1	Mild 1	
		Overall change/physician	Mid (12)	Excellent 31 Good 21 Partially improved 17 Not improved 10	Excellent 8 Good 12 Partially improved 25 Not improved 23	**0.001**
		Pruritis	Mid (12)	Worse 2 Mild 2 Not stated 1	Worse 7 Mild 9 Not stated	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
184 ↑ Parallel Mod N=175		**Redness**	Mid (12)	Mild 4 Moderate 0 Severe 1	Mild 6 Moderate 3 Severe 0	
		Scaling	Mid (12)	Mild 4 Moderate 2 Severe 0	Mild 3 Moderate 4 Severe 1	
		Side effects	Mid (12)	Any (continued) 15 Any (withdraw) 2	Any (continued) 17 Any (withdraw) 4	
205 Parallel Mild/mod N=225		**Erythema**	Mid (12)	None 84 Mild 18 Moderate 2 Moderate severe 1 Severe 0	None 82 Mild 18 Moderate 2 Moderate severe 1 Severe 0	
		Peeling	Mid (12)	None 95 Mild 8 Moderate 2 Moderate severe 0 Severe 0	None 96 Mild 5 Moderate 2 Moderate severe 0 Severe 0	
277 Parallel split face Mild/mod N=73		**Lesions change**	Mid (8)	Any change less than 0 51 50% or less change 21	Any change less than 0 40 50% or less change 14	**NS**
	C.04.01			**Fusiden**	**Vehicle**	
151 Parallel Mild/mod N=79		**Side effects**	Short (3)	Mild itching 1 Diffuse exanthema 0 None 35	Mild itching 0 Diffuse exanthema 1 None 33	
	C.05.01			**Meclocycline**	**Benzoyl peroxide**	
30 ↑ Parallel Mod N=102		**Skin discoloration**	Mid (10)	Present 2 Absent 31	Present 1 Absent 35	
	C.06.01			**Metronidazole**	**Placebo**	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
328 ↑ Parallel Mild/mod N=96		**Local irritation**		Present 2 Absent 46	Present 1 Absent 47	
		Side effects	Mid (8)	Redness 0 Dryness 0	Redness 0 Dryness 0	
	C.08.01			**Tetracycline (topical) + placebo (oral)**	**Vehicle (topical) + placebo (oral)**	
10 Parallel Mod N=60		**Severity change**	Mid (8)	> 1 unit decrease 14 < 1 unit decrease 3 No change 2	> 1 unit decrease 6 < 1 unit decrease 4 No change 7	**NS**
	C.08.03			**Tetracycline (topical) + placebo (oral)**	**Benzoyl peroxide + placebo (oral)**	
255 Parallel Mod N=69		**Side effects**	Mid (12)	Severe facial reaction 0 GI symptoms 2 Vaginal candidiasis 0	Severe facial reaction 1 GI symptoms 2 Vaginal candidiasis 1	
	C.09.02			**Triclosan**	**Phisohex**	
21 Cross-over Mild/mod/sev N=34		**Overall change/patient** Between P-value: Where pt & doctor agreed, pref was for triclosan, p. 05	Short (6)	Worse 6 No change 2 Some improvement 11 Marked improvement 12 Not answered 2	Worse 3 No change 11 Some change 11 Marked improvement 6 Not answered 2	**NS**
		Overall change/physician Between P-value: Where pt & doctor agreed, pref was for triclosan, p. 05	Short (6)	No change 7 Some improvement 16 Marked improvement 6 Not answered 4	No change 10 Some improvement 15 Marked improvement 6 Not answered 2	**NS**
		Side effects	Short (6)	Local drying/scaling/itching 11 Erythema/soreness (withdraw) 2	Local drying/scaling/itching 9 Erythema/soreness (withdraw) 3	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.